• Voyager Therapeutics (NASDAQ:VYGR) has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer’s disease.
• Stock up 4% premarket.
• The company anticipates filing an investigational new drug application with the U.S. Food and Drug Administration and a clinical trial application with Health Canada for VY1706 in 2026.
• Source: Press Release

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.